Lengo Therapeutics, Inc. — Form D/A
Lengo Therapeutics, Inc. of Menlo Park, CA, a company, filed a Form D amendment with the SEC on 2021-04-30. The offering totals $17.7M, of which $17.7M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2021-04-30
- Form: D/A
- Accession: 0001567619-21-008808
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $17.7M
- Amount sold: $17.7M
- Investors: 4
- Date of first sale: 2020-03-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-364705
Issuer
- Name: Lengo Therapeutics, Inc.
- CIK: 0001808546
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 70 Willow Road, Suite 200, Menlo Park, CA, 94025
- Phone: (650) 325-5156
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Daniel Estes, Ph.D. | Director | Menlo Park, CA |
| Helen Jenkins | Director | Menlo Park, CA |
| David Johnson | Director | Greenwood Village, CO |
| Tracy Saxton, Ph.D. | Director | Menlo Park, CA |
| Roger Ulrich, Ph.D. | Director | Menlo Park, CA |
| STEVE BAILEY | Executive Officer | SEATTLE, WA |
| Anna Chen | Executive Officer | Palo Alto, CA |
| Daniel Estes, Ph.D. | Executive Officer | Menlo Park, CA |
| Helen Jenkins | Executive Officer | Menlo Park, CA |
| Tracy Saxton, Ph.D. | Executive Officer | Menlo Park, CA |
Other filings by this issuer (1)
More